Compositon/Ingredients: Filgrastim

- Filgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
- The safety and efficacy of Filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
- Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
- In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Filgrastim is indicated for the treatment of persistent neutropenia (Absolute neutrophil count (ANC) less than or equal to 1.0 x109/L) in patients with advanced HIV infection inappropriate.

- Hypersensitivity to the active substance or to any of the excipients. Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.
- With severe congenital neutropenia (Kostman's syndrome) with abnormal cytogenetics.

Store at 2°C - 8°C. Do not freeze. Protect from light. The solution for injection should be inspected visually for particulate matter and discoloration before administration.